2024年国家卫健委启动为期三年的“体重管理年”以来,体重管理、减重等成为大热词汇,不少市民熟悉的“减肥针”不断“上新”,减重热潮带来研发热潮,减重赛道也随之“卷”了起来。 记者梳理,目前临床广泛应用的包括来自丹麦诺和诺德的司美格鲁肽、来自美国礼来的替尔泊肽,以及我国信达生物自主研发的玛仕度肽。此外,还包括业界高度关注的来自美国辉瑞的埃诺格鲁肽。这些“减肥针”具体都有哪些区别?适合哪些不同的人群...
Source Link2024年国家卫健委启动为期三年的“体重管理年”以来,体重管理、减重等成为大热词汇,不少市民熟悉的“减肥针”不断“上新”,减重热潮带来研发热潮,减重赛道也随之“卷”了起来。 记者梳理,目前临床广泛应用的包括来自丹麦诺和诺德的司美格鲁肽、来自美国礼来的替尔泊肽,以及我国信达生物自主研发的玛仕度肽。此外,还包括业界高度关注的来自美国辉瑞的埃诺格鲁肽。这些“减肥针”具体都有哪些区别?适合哪些不同的人群...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.